KR100854211B1 - 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 - Google Patents

신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 Download PDF

Info

Publication number
KR100854211B1
KR100854211B1 KR1020040058809A KR20040058809A KR100854211B1 KR 100854211 B1 KR100854211 B1 KR 100854211B1 KR 1020040058809 A KR1020040058809 A KR 1020040058809A KR 20040058809 A KR20040058809 A KR 20040058809A KR 100854211 B1 KR100854211 B1 KR 100854211B1
Authority
KR
South Korea
Prior art keywords
fluorophenyl
pyridin
methyl
methyltetrazol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020040058809A
Other languages
English (en)
Korean (ko)
Other versions
KR20050061271A (ko
Inventor
이재걸
임원빈
조종환
최성학
이태호
Original Assignee
동아제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36660051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100854211(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 동아제약주식회사 filed Critical 동아제약주식회사
Priority to KR1020040058809A priority Critical patent/KR100854211B1/ko
Priority to PCT/KR2004/003327 priority patent/WO2005058886A1/en
Priority to US10/596,412 priority patent/US7816379B2/en
Priority to PL04808458T priority patent/PL1699784T3/pl
Priority to CN2004800376122A priority patent/CN1894242B/zh
Priority to EP04808458A priority patent/EP1699784B1/en
Priority to NZ547928A priority patent/NZ547928A/en
Priority to AT04808458T priority patent/ATE514686T1/de
Priority to DK04808458.6T priority patent/DK1699784T3/da
Priority to EP10183967A priority patent/EP2305657B1/en
Priority to CN2010105088241A priority patent/CN101982468B/zh
Priority to CN201110304983.4A priority patent/CN102516238B/zh
Priority to BRPI0417800A priority patent/BRPI0417800B8/pt
Priority to AU2004299413A priority patent/AU2004299413C1/en
Priority to PT04808458T priority patent/PT1699784E/pt
Priority to JP2006545238A priority patent/JP4739229B2/ja
Priority to ES10183967T priority patent/ES2391820T3/es
Priority to RU2010149618/04A priority patent/RU2559620C2/ru
Priority to MX2012012028A priority patent/MX339597B/es
Priority to NZ575842A priority patent/NZ575842A/en
Priority to CN201210155386.4A priority patent/CN102702184B/zh
Priority to CA2549062A priority patent/CA2549062C/en
Priority to RU2006125761A priority patent/RU2414469C3/ru
Priority to SI200431751T priority patent/SI1699784T1/sl
Priority to MXPA06006955A priority patent/MXPA06006955A/es
Publication of KR20050061271A publication Critical patent/KR20050061271A/ko
Application granted granted Critical
Publication of KR100854211B1 publication Critical patent/KR100854211B1/ko
Priority to US12/211,655 priority patent/US8420676B2/en
Priority to AU2009200606A priority patent/AU2009200606B2/en
Priority to HK11107829.9A priority patent/HK1153738B/xx
Priority to HK11110172.6A priority patent/HK1155747B/en
Priority to CY20111100939T priority patent/CY1112445T1/el
Priority to US13/863,216 priority patent/US9163043B2/en
Priority to US14/459,161 priority patent/US20140350059A1/en
Priority to NL300759C priority patent/NL300759I1/nl
Priority to HUS1500046C priority patent/HUS1500046I1/hu
Priority to BE2015C050C priority patent/BE2015C050I2/fr
Priority to LU92834C priority patent/LU92834I2/xx
Priority to CY2015036C priority patent/CY2015036I2/el
Priority to LTPA2015032C priority patent/LTC1699784I2/lt
Priority to FR15C0062C priority patent/FR15C0062I2/fr
Priority to US15/251,049 priority patent/US20170049763A1/en
Priority to US15/616,021 priority patent/US20170333414A1/en
Priority to US16/054,538 priority patent/US20180344716A1/en
Priority to US16/681,206 priority patent/US20200078345A1/en
Priority to US16/895,816 priority patent/US20210121449A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020040058809A 2003-12-18 2004-07-27 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 Expired - Fee Related KR100854211B1 (ko)

Priority Applications (44)

Application Number Priority Date Filing Date Title
KR1020040058809A KR100854211B1 (ko) 2003-12-18 2004-07-27 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
PCT/KR2004/003327 WO2005058886A1 (en) 2003-12-18 2004-12-17 Novel oxazolidinone derivatives
US10/596,412 US7816379B2 (en) 2003-12-18 2004-12-17 Oxazolidinone derivatives
PL04808458T PL1699784T3 (pl) 2003-12-18 2004-12-17 Nowe pochodne oksazolidynonowe
CN2004800376122A CN1894242B (zh) 2003-12-18 2004-12-17 新型噁唑烷酮衍生物
EP04808458A EP1699784B1 (en) 2003-12-18 2004-12-17 Novel oxazolidinone derivatives
NZ547928A NZ547928A (en) 2003-12-18 2004-12-17 Novel oxazolidinone derivatives
AT04808458T ATE514686T1 (de) 2003-12-18 2004-12-17 Neue oxazolidinonderivate
DK04808458.6T DK1699784T3 (da) 2003-12-18 2004-12-17 Nye oxazolidinonderivater
EP10183967A EP2305657B1 (en) 2003-12-18 2004-12-17 Oxazolidinone derivatives
CN2010105088241A CN101982468B (zh) 2003-12-18 2004-12-17 噁唑烷酮衍生物以及含有该衍生物的药物组合物
CN201110304983.4A CN102516238B (zh) 2003-12-18 2004-12-17 噁唑烷酮衍生物
BRPI0417800A BRPI0417800B8 (pt) 2003-12-18 2004-12-17 derivados de oxazolidinona e sua composição farmacêutica
AU2004299413A AU2004299413C1 (en) 2003-12-18 2004-12-17 Novel oxazolidinone derivatives
PT04808458T PT1699784E (pt) 2003-12-18 2004-12-17 Novos derivados de oxazolidinona
JP2006545238A JP4739229B2 (ja) 2003-12-18 2004-12-17 新規オキサゾリジノン誘導体
ES10183967T ES2391820T3 (es) 2003-12-18 2004-12-17 Derivados de oxazolidinona
RU2010149618/04A RU2559620C2 (ru) 2003-12-18 2004-12-17 Новые производные оксазолидинона, способ их получения и применение
MX2012012028A MX339597B (es) 2003-12-18 2004-12-17 Derivados de oxazolidinona novedosos.
NZ575842A NZ575842A (en) 2003-12-18 2004-12-17 Novel oxazolidinone derivatives
CN201210155386.4A CN102702184B (zh) 2003-12-18 2004-12-17 噁唑烷酮衍生物
CA2549062A CA2549062C (en) 2003-12-18 2004-12-17 Novel oxazolidinone derivatives
RU2006125761A RU2414469C3 (ru) 2003-12-18 2004-12-17 Новые производные оксазолидинона
SI200431751T SI1699784T1 (sl) 2003-12-18 2004-12-17 Novi oksazolidinonski derivti
MXPA06006955A MXPA06006955A (es) 2003-12-18 2004-12-17 Derivados de oxazolidinona novedosos.
US12/211,655 US8420676B2 (en) 2003-12-18 2008-09-16 Oxazolidinone derivatives
AU2009200606A AU2009200606B2 (en) 2003-12-18 2009-02-17 Novel oxazolidinone derivatives
HK11107829.9A HK1153738B (en) 2003-12-18 2011-07-27 Oxazolidinone derivatives and pharmaceutical composition comprising the same
HK11110172.6A HK1155747B (en) 2003-12-18 2011-09-27 Oxazolidinone derivatives
CY20111100939T CY1112445T1 (el) 2003-12-18 2011-09-28 Νεα παραγωγα οξαζολιδινονης
US13/863,216 US9163043B2 (en) 2003-12-18 2013-04-15 Oxazolidinone derivatives
US14/459,161 US20140350059A1 (en) 2003-12-18 2014-08-13 Novel oxazolidinone derivatives
NL300759C NL300759I1 (enExample) 2003-12-18 2015-09-01
HUS1500046C HUS1500046I1 (hu) 2003-12-18 2015-09-03 Új oxazolidinon-származékok
BE2015C050C BE2015C050I2 (enExample) 2003-12-18 2015-09-17
LU92834C LU92834I2 (fr) 2003-12-18 2015-09-17 Tédizolide, optionnellement sous la forme d'un ester, en particulier un phosphate ou un sel de celui-ci pharmaceutiquement acceptable
CY2015036C CY2015036I2 (el) 2003-12-18 2015-09-18 Νεα παραγωγα οξαζολιδινονης
LTPA2015032C LTC1699784I2 (lt) 2003-12-18 2015-09-22 Nauji oksazolidinono dariniai
FR15C0062C FR15C0062I2 (fr) 2003-12-18 2015-09-22 Nouveaux derives d'oxazolidinone
US15/251,049 US20170049763A1 (en) 2003-12-18 2016-08-30 Novel oxazolidinone derivatives
US15/616,021 US20170333414A1 (en) 2003-12-18 2017-06-07 Novel oxazolidinone derivatives
US16/054,538 US20180344716A1 (en) 2003-12-18 2018-08-03 Novel oxazolidinone derivatives
US16/681,206 US20200078345A1 (en) 2003-12-18 2019-11-12 Novel oxazolidinone derivatives
US16/895,816 US20210121449A1 (en) 2003-12-18 2020-06-08 Novel oxazolidinone derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20030093342 2003-12-18
KR1020030093342 2003-12-18
KR1020040058809A KR100854211B1 (ko) 2003-12-18 2004-07-27 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물

Publications (2)

Publication Number Publication Date
KR20050061271A KR20050061271A (ko) 2005-06-22
KR100854211B1 true KR100854211B1 (ko) 2008-08-26

Family

ID=36660051

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020040058809A Expired - Fee Related KR100854211B1 (ko) 2003-12-18 2004-07-27 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물

Country Status (25)

Country Link
US (9) US7816379B2 (enExample)
EP (2) EP1699784B1 (enExample)
JP (1) JP4739229B2 (enExample)
KR (1) KR100854211B1 (enExample)
CN (4) CN101982468B (enExample)
AT (1) ATE514686T1 (enExample)
AU (2) AU2004299413C1 (enExample)
BE (1) BE2015C050I2 (enExample)
BR (1) BRPI0417800B8 (enExample)
CA (1) CA2549062C (enExample)
CY (2) CY1112445T1 (enExample)
DK (1) DK1699784T3 (enExample)
ES (1) ES2391820T3 (enExample)
FR (1) FR15C0062I2 (enExample)
HU (1) HUS1500046I1 (enExample)
LT (1) LTC1699784I2 (enExample)
LU (1) LU92834I2 (enExample)
MX (2) MXPA06006955A (enExample)
NL (1) NL300759I1 (enExample)
NZ (2) NZ547928A (enExample)
PL (1) PL1699784T3 (enExample)
PT (1) PT1699784E (enExample)
RU (2) RU2414469C3 (enExample)
SI (1) SI1699784T1 (enExample)
WO (1) WO2005058886A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2492264A3 (en) 2003-06-03 2012-12-19 Rib-X Pharmaceuticals, Inc. Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
AR046782A1 (es) 2003-12-17 2005-12-21 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos.
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
MXPA06013540A (es) * 2004-05-25 2007-01-26 Astrazeneca Ab Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas.
EP1799677A1 (en) * 2004-10-08 2007-06-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
ATE496914T1 (de) 2005-06-08 2011-02-15 Rib X Pharmaceuticals Inc Verfahren zur synthese von triazolen
CN100406455C (zh) * 2006-02-20 2008-07-30 中国科学院上海药物研究所 含三氮唑基的噁唑烷酮类化合物及其制备方法和用途
US8124623B2 (en) 2006-11-10 2012-02-28 Actelion Pharmaceuticals Ltd. 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials
JP4484965B2 (ja) * 2006-11-10 2010-06-16 アクテリオン ファーマシューティカルズ リミテッド ５−ヒドロキシメチル−オキサゾリジン−２−オン誘導体
NZ589734A (en) 2008-05-09 2012-11-30 Actelion Pharmaceuticals Ltd 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
WO2010047737A2 (en) 2008-09-02 2010-04-29 Micurx Pharmaceuticals, Inc. Antimicrobial indoline compounds for treatment of bacterial infections
MX2011003820A (es) * 2008-10-10 2011-06-16 Trius Therapeutics Metodos para preparar oxazolidinonas y composiciones que las contienen.
MY161597A (en) 2008-11-15 2017-04-28 Rib-X Pharmaceuticals Inc Antimicrobial compositions
AU2009318783A1 (en) 2008-11-20 2011-06-23 Panacea Biotec Ltd. Novel antimicrobials
TW201033226A (en) 2008-11-28 2010-09-16 Chugai Pharmaceutical Co Ltd 1-(2h)-isoquinolone derivative
CN107082790A (zh) 2009-02-03 2017-08-22 默沙东公司 一种噁唑烷酮化合物的晶型
CN101798302B (zh) 2009-02-06 2014-11-05 上海盟科药业有限公司 抗生素类药物1-(邻-氟苯基)二氢吡啶酮的合成及生产的方法和工艺
CA2754712A1 (en) * 2009-03-13 2010-09-16 Sun Chemical B.V. Cyclic carbamate compounds useful in energy-curable compositions
US8580767B2 (en) * 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
JP5696142B2 (ja) 2009-06-26 2015-04-08 パナセア バイオテック リミテッド 新規アザビシクロヘキサン類
EP3095445A1 (en) * 2009-10-13 2016-11-23 Melinta Therapeutics, Inc. Pharmaceutical compositions comprising radezolid
IT1397023B1 (it) 2009-11-27 2012-12-20 Professional Dietetics Srl Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva
ES2368236B1 (es) * 2009-12-23 2012-09-26 Merck Sharp & Dohme Corp. Agentes antibacterianos.
CN102276595A (zh) * 2010-04-16 2011-12-14 山东轩竹医药科技有限公司 含有五元杂环的噁唑烷酮抗菌素
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
WO2012033952A1 (en) 2010-09-10 2012-03-15 Micurx Pharmaceuticals, Inc. 3 - phenyl- 2 -oxo- 1, 3 -oxazolidines for treatment of bacterial infections
JP5902188B2 (ja) 2010-11-01 2016-04-13 メリンタ セラピューティクス，インコーポレイテッド 薬学的組成物
ES2836809T3 (es) 2010-11-24 2021-06-28 Melinta Subsidiary Corp Composiciones farmacéuticas
CN103415511B (zh) * 2011-01-31 2016-01-20 国立大学法人长崎大学 光学活性化合物或其盐的制造方法
KR101653570B1 (ko) * 2011-03-30 2016-09-02 주식회사 레고켐 바이오사이언스 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
EP2762479A4 (en) 2011-09-29 2015-04-22 Xuanzhu Pharma Co Ltd OXAZOLIDINONE ANTIBACTERIAL MEDICINE BASED ON BIARYLIC HETEROCYCLE SUBSTITUTED
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
CN103896963B (zh) * 2012-12-26 2017-06-09 中国科学院上海药物研究所 苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CA2904387C (en) 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
KR101480982B1 (ko) * 2013-03-20 2015-02-03 (주)셀인바이오 골형성 유도 화합물 및 이의 응용
CN104650142B (zh) * 2013-11-25 2018-06-22 山东新时代药业有限公司 一种福沙匹坦二甲葡胺的制备方法
CA2939098A1 (en) 2014-02-21 2015-08-27 Micurx Pharmaceuticals, Inc. Water-soluble o-carbonyl phosphoramidate prodrugs for therapeutic administration
CN105229001B (zh) * 2014-04-18 2017-04-26 杭州普晒医药科技有限公司 一种噁唑烷酮类抗生素的晶型及制备方法、组合物和用途
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
WO2016009401A2 (en) * 2014-07-18 2016-01-21 Dr. Reddy's Laboratories Limited Preparation of tedizolid phosphate
CN105566392B (zh) * 2014-10-15 2018-12-21 正大天晴药业集团股份有限公司 一种细菌蛋白质合成抑制剂的制备方法
CN105503955B (zh) * 2014-10-15 2018-11-20 正大天晴药业集团股份有限公司 一种抗革兰氏阳性菌的化合物的制备方法
WO2016041505A1 (zh) * 2014-09-17 2016-03-24 正大天晴药业集团股份有限公司 一种磷酸特地唑胺、其中间体以及它们的制备方法
CN106928214A (zh) * 2014-09-17 2017-07-07 博瑞生物医药（苏州）股份有限公司 一种噁唑烷酮类化合物及其中间体的制备方法
CN105418678B (zh) * 2014-09-17 2018-11-20 正大天晴药业集团股份有限公司 一种磷酸特地唑胺的制备方法
CN105837633B (zh) * 2015-01-12 2018-11-20 正大天晴药业集团股份有限公司 一种抗菌化合物的制备方法
CN104327119A (zh) * 2014-10-17 2015-02-04 苏州明锐医药科技有限公司 磷酸泰地唑胺的制备方法
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
WO2016088100A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088101A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited Processes for the preparation of tedizolid phosphate and its intermediates
WO2016088103A1 (en) * 2014-12-05 2016-06-09 Sun Pharmaceutical Industries Limited A process for the preparation of tedizolid phosphate
CN104530128B (zh) * 2014-12-30 2016-08-24 石药集团中诺药业（石家庄）有限公司 一种磷酸特地唑胺二钠盐及其制备方法
CN104558034A (zh) * 2015-01-21 2015-04-29 齐鲁制药有限公司 磷酸特地唑胺二钠盐的新晶型及其制备方法
CN105859780A (zh) * 2015-01-21 2016-08-17 山东康美乐医药科技有限公司 磷酸特地唑胺的制备方法
CN104610359B (zh) * 2015-01-26 2017-07-14 成都新恒创药业有限公司 一种制备磷酸特地唑胺的关键中间体及其制备方法
CN105837634B (zh) * 2015-01-30 2020-09-04 上海创诺制药有限公司 一种泰地唑胺磷酸酯结晶体及其制备方法
CN104592218B (zh) * 2015-02-13 2015-11-04 江苏欧信医药化工有限公司 一种泰地唑胺的合成方法
CN110078764B (zh) * 2015-04-10 2021-10-26 博瑞生物医药（苏州）股份有限公司 一种噁唑烷酮类化合物的制备方法
CN106146558A (zh) * 2015-04-10 2016-11-23 博瑞生物医药（苏州）股份有限公司 新的噁唑烷酮类化合物及其制备方法
CN106279281B (zh) * 2015-05-15 2018-08-03 重庆圣华曦药业股份有限公司 噁唑烷酮类抗菌素泰地唑胺磷酸酯的精制方法
CN106317114B (zh) * 2015-07-02 2018-11-20 南京优科制药有限公司 一种磷酸特地唑胺的制备方法
CN106632298B (zh) 2015-11-03 2021-06-01 上海科胜药物研发有限公司 一种泰地唑胺的制备方法及其中间体
KR101855334B1 (ko) 2015-12-11 2018-06-08 에스티팜 주식회사 옥사졸리디논 유도체의 중간체 제조방법
CN105496976A (zh) * 2015-12-18 2016-04-20 北京万全德众医药生物技术有限公司 一种磷酸特地唑胺片及其制备方法
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
CN106083994B (zh) * 2016-04-18 2019-12-06 南京曼杰生物科技有限公司 取代的噁唑烷酮水溶性衍生物及其应用
WO2017181948A1 (zh) * 2016-04-22 2017-10-26 深圳市塔吉瑞生物医药有限公司 取代的恶唑烷酮化合物及其应用
CN107400126A (zh) * 2016-05-19 2017-11-28 陕西合成药业股份有限公司 新型噁唑烷酮类化合物及其制备方法和在医学上的应用
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN106632240A (zh) * 2016-11-25 2017-05-10 山东轩德医药科技有限公司 一种2‑甲基‑5‑(5‑溴吡啶‑2‑基)四氮唑的制备方法
US10087171B2 (en) 2016-12-19 2018-10-02 Actelion Pharmaceuticals Ltd Crystalline forms of cadazolid
CN107226825B (zh) * 2017-06-14 2019-08-02 浙江海正药业股份有限公司 磷酸泰地唑胺铵盐及其晶型、制备方法和医药用途
EP3723758A4 (en) 2017-12-13 2021-06-23 Merck Sharp & Dohme Corp. PHARMACEUTICAL COMPOSITIONS OF TEDICOLIDE PHOSPHATE
CN110804038B (zh) * 2018-08-06 2021-03-05 上海博志研新药物技术有限公司 磷酸特地唑胺及其中间体的制备方法
WO2020147504A1 (en) * 2019-01-18 2020-07-23 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2021000297A1 (en) 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Compounds and methods of use thereof as antibacterial agents
CN117567455A (zh) * 2019-12-11 2024-02-20 华创合成制药股份有限公司 一种新型噁唑烷酮类化合物及其合成方法和应用
CN111116551B (zh) * 2020-01-03 2022-05-20 中国医科大学 1-氮杂螺[5.5]十一烷-3-酮类及1-氮杂螺[5.5]十一烷-3-醇类化合物
CN115968290A (zh) * 2020-06-18 2023-04-14 阿卡格拉医药公司 噁唑烷酮类化合物、包含噁唑烷酮类化合物的脂质体组合物、及其使用方法
AU2021292747A1 (en) 2020-06-18 2023-02-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
CN114315897B (zh) * 2020-09-30 2024-05-17 北京澳合药物研究院有限公司 一种磷酸特地唑胺新晶体及其制备方法
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
CN112500433A (zh) * 2020-12-23 2021-03-16 桂林南药股份有限公司 一种磷酸特地唑胺的制备方法
CN113197874B (zh) * 2021-04-28 2023-05-26 北京福元医药股份有限公司 一种磷酸特地唑胺口服固体制剂
AU2022420614A1 (en) * 2021-12-22 2024-06-27 Akagera Medicines, Inc. Oxazolidinone liposome compositions
JP2025522311A (ja) 2022-05-25 2025-07-15 アカゲラ・メディスンズ，インコーポレイテッド 核酸を送達するための脂質ナノ粒子およびその使用方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352781A2 (en) 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5977373A (en) 1997-07-11 1999-11-02 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
KR20010043695A (ko) * 1998-05-18 2001-05-25 로렌스 티. 마이젠헬더 아르기닌 유도체를 사용한 옥사졸리디논 항균제 활성의증진 방법
KR20010110057A (ko) * 2000-06-05 2001-12-12 유충식 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법
KR20020071576A (ko) * 2001-03-07 2002-09-13 동아제약 주식회사 헤테로고리 또는 헤테로아로마틱 고리가 치환된 피리딘고리를 포함하는 옥사졸리디논 유도체 및 그의 제조방법
US20020133022A1 (en) 1996-02-24 2002-09-19 Gravestock Michael Barry Antibiotic oxazolidinone derivatives
WO2005058886A1 (en) 2003-12-18 2005-06-30 Dong-A Pharm.Co.,Ltd. Novel oxazolidinone derivatives

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4340606A (en) 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2500450A1 (fr) 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US4461773A (en) 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
CA1320730C (en) 1987-10-16 1993-07-27 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
KR100257418B1 (ko) * 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
EP0673370B1 (en) * 1992-12-08 1998-01-07 PHARMACIA & UPJOHN COMPANY Tropone-substituted phenyloxazolidinone antibacterial agents
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
AU698699B2 (en) 1993-11-22 1998-11-05 Pharmacia & Upjohn Company Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones
CA2228647A1 (en) * 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
CN1154644C (zh) * 1997-11-12 2004-06-23 法玛西雅厄普约翰美国公司 噁唑烷酮衍生物和药物组合物
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
GB0009803D0 (en) 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
BR0111280A (pt) 2000-06-05 2003-06-10 Dong A Pharm Co Ltd Novos derivados de oxazolidinona e um processo para a preparação dos mesmos
US20020115669A1 (en) 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
YU52403A (sh) 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
ES2268011T3 (es) 2001-04-07 2007-03-16 Astrazeneca Ab Oxazolidinonas que contienen un grupo sulfonimida como antibioticos.
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CN1639136A (zh) 2001-09-11 2005-07-13 阿斯特拉曾尼卡有限公司 作为抗菌剂的噁唑烷酮和/或异噁唑啉
EP1446403B1 (en) 2001-10-25 2006-04-12 AstraZeneca AB Aryl substituted oxazolidinones with antibacterial activity
NZ515881A (en) 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
AU2003207340A1 (en) * 2002-02-28 2003-09-09 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
KR20040086465A (ko) 2002-02-28 2004-10-08 아스트라제네카 아베 화합물
BR0316688A (pt) 2002-11-28 2005-10-18 Astrazeneca Ab Composto, prodroga de um composto, método de produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
US7498350B2 (en) 2002-11-28 2009-03-03 Astrazeneca Ab Oxazolidinones as antibacterial agents
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
TW200500360A (en) 2003-03-01 2005-01-01 Astrazeneca Ab Hydroxymethyl compounds
GB0306358D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
WO2005005398A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
WO2005005420A1 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Cyclopropyl group substituted oyazolidinone antibiotics and derivatives thereof
WO2005051933A1 (en) 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
AR046782A1 (es) * 2003-12-17 2005-12-21 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos.
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
MXPA06013540A (es) 2004-05-25 2007-01-26 Astrazeneca Ab Derivados de 3-(4-(2 -dihidroisoxasol -3-ilpiridin-5-il) fenil)-5- triazol-1- ilmetiloxazolidin -2-ona como inhibidores de mao para el tratamiento de infecciones bacterianas.
US20080021071A1 (en) 2004-05-25 2008-01-24 Astrazeneca Ab 3-{4-(Pyridin-3-Yl) Phenyl}-5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
US20080064689A1 (en) 2004-05-25 2008-03-13 Astrazeneca Ab 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents
AU2005247668A1 (en) 2004-05-25 2005-12-08 Astrazeneca Ab 3- `4- {6-substituted alkanoyl) pyridin-3-yl} -3-phenyl! -5- (1H-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents
GB0411596D0 (en) 2004-05-25 2004-06-30 Astrazeneca Ab Chemical process
EP1799677A1 (en) 2004-10-08 2007-06-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US20090018123A1 (en) 2005-06-20 2009-01-15 Milind D Sindkhedkar Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation
WO2007138381A2 (en) 2005-10-14 2007-12-06 Targanta Therapeutics Inc. Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
JP5455906B2 (ja) 2007-08-06 2014-03-26 ミクウルク ファーマシューティカルズ，インコーポレイテッド 細菌感染症治療のための抗微生物性オルト−フルオロフェニルオキサゾリジノン
MX2011003820A (es) 2008-10-10 2011-06-16 Trius Therapeutics Metodos para preparar oxazolidinonas y composiciones que las contienen.
CN107082790A (zh) 2009-02-03 2017-08-22 默沙东公司 一种噁唑烷酮化合物的晶型
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352781A2 (en) 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US20020133022A1 (en) 1996-02-24 2002-09-19 Gravestock Michael Barry Antibiotic oxazolidinone derivatives
US5977373A (en) 1997-07-11 1999-11-02 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
KR20010043695A (ko) * 1998-05-18 2001-05-25 로렌스 티. 마이젠헬더 아르기닌 유도체를 사용한 옥사졸리디논 항균제 활성의증진 방법
KR20010110057A (ko) * 2000-06-05 2001-12-12 유충식 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법
KR20020071576A (ko) * 2001-03-07 2002-09-13 동아제약 주식회사 헤테로고리 또는 헤테로아로마틱 고리가 치환된 피리딘고리를 포함하는 옥사졸리디논 유도체 및 그의 제조방법
WO2005058886A1 (en) 2003-12-18 2005-06-30 Dong-A Pharm.Co.,Ltd. Novel oxazolidinone derivatives

Also Published As

Publication number Publication date
CN102702184B (zh) 2016-06-08
EP1699784A4 (en) 2008-09-03
US20130281492A1 (en) 2013-10-24
US20180344716A1 (en) 2018-12-06
HUS1500046I1 (hu) 2017-05-29
US9163043B2 (en) 2015-10-20
CY2015036I1 (el) 2016-06-22
MX339597B (es) 2016-06-01
CA2549062A1 (en) 2005-06-30
CN102516238B (zh) 2016-08-03
AU2004299413B2 (en) 2008-11-20
NZ547928A (en) 2009-05-31
US20210121449A1 (en) 2021-04-29
CY2015036I2 (el) 2016-06-22
KR20050061271A (ko) 2005-06-22
NZ575842A (en) 2010-10-29
CY1112445T1 (el) 2015-12-09
CN1894242A (zh) 2007-01-10
SI1699784T1 (sl) 2011-11-30
CN101982468B (zh) 2012-02-08
AU2009200606A1 (en) 2009-03-05
PT1699784E (pt) 2011-10-06
LU92834I2 (fr) 2015-11-17
BRPI0417800B8 (pt) 2021-05-25
PL1699784T3 (pl) 2011-11-30
EP1699784A1 (en) 2006-09-13
ATE514686T1 (de) 2011-07-15
US7816379B2 (en) 2010-10-19
EP1699784B1 (en) 2011-06-29
AU2009200606B2 (en) 2011-01-06
FR15C0062I2 (fr) 2016-08-26
JP2007514737A (ja) 2007-06-07
EP2305657B1 (en) 2012-08-22
BE2015C050I2 (enExample) 2024-08-08
RU2414469C3 (ru) 2017-06-14
WO2005058886A1 (en) 2005-06-30
BRPI0417800B1 (pt) 2019-10-08
CA2549062C (en) 2011-07-05
US20140350059A1 (en) 2014-11-27
DK1699784T3 (da) 2011-10-10
AU2004299413C1 (en) 2009-07-02
HK1153738A1 (en) 2012-04-05
BRPI0417800A (pt) 2007-04-10
NL300759I2 (enExample) 2015-12-22
CN1894242B (zh) 2012-07-04
CN101982468A (zh) 2011-03-02
CN102516238A (zh) 2012-06-27
ES2391820T3 (es) 2012-11-30
MXPA06006955A (es) 2006-12-19
US20090192197A1 (en) 2009-07-30
RU2010149618A (ru) 2012-06-27
RU2006125761A (ru) 2008-01-27
US20200078345A1 (en) 2020-03-12
NL300759I1 (enExample) 2015-12-22
FR15C0062I1 (fr) 2015-10-30
US20070155798A1 (en) 2007-07-05
JP4739229B2 (ja) 2011-08-03
HK1155747A1 (en) 2012-05-25
US20170333414A1 (en) 2017-11-23
US20170049763A1 (en) 2017-02-23
US8420676B2 (en) 2013-04-16
CN102702184A (zh) 2012-10-03
EP2305657A2 (en) 2011-04-06
RU2414469C2 (ru) 2011-03-20
AU2004299413A1 (en) 2005-06-30
EP2305657A3 (en) 2011-04-27
RU2559620C2 (ru) 2015-08-10
LTC1699784I2 (lt) 2017-09-11

Similar Documents

Publication Publication Date Title
KR100854211B1 (ko) 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US6689779B2 (en) Oxazolidinone derivatives and a process for the preparation thereof
CZ34197A3 (en) Heteroaryl-oxazolidinones, process of their preparation, their use and pharmaceutical composition containing thereof
KR100731469B1 (ko) 피리딘 고리를 포함하는 옥사졸리디논 유도체 및 그의제조방법
KR100948345B1 (ko) 신규한 옥사졸리디논 유도체, 이의 제조방법 및 이를함유하는 의약 조성물
KR100713170B1 (ko) 헤테로고리 또는 헤테로아로마틱 고리가 치환된 피리딘고리를 포함하는 옥사졸리디논 유도체 및 그의 제조방법
KR100674096B1 (ko) 피리미딘 고리를 포함하는 신규 옥사졸리디논 유도체와그의 제조방법
ES2368918T3 (es) Nuevos derivados de oxazolidinona.
HK1153738B (en) Oxazolidinone derivatives and pharmaceutical composition comprising the same
HK1155747B (en) Oxazolidinone derivatives

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20121231

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20131226

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20141211

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 1, Claim Number : 13, Period Limitation Text : 238, Comment Text : 31 42 5112

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 1, Claim Number : 13, Period Limitation Text : 238, Comment Text : 31 42 5112

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20161222

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20171219

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20181217

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

FPAY Annual fee payment

Payment date: 20191126

Year of fee payment: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 15

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 16

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240820

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240820